ResMed (RMD) Stock Price, News & Analysis

Company Overview

ResMed Inc. (NYSE: RMD) develops, manufactures and distributes medical equipment and digital health solutions for sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its products include continuous positive airway pressure (CPAP), bilevel and other noninvasive ventilation devices, as well as masks, humidifiers, accessories and diagnostic equipment.

The company also provides cloud-connected software and digital health services that support patient monitoring, therapy management and communication among patients, clinicians and care providers. Through its out-of-hospital care offerings, including healthcare software obtained through Brightree, ResMed serves providers involved in home medical equipment, home health and related post-acute care services.

ResMed was founded in Australia in 1989 and is headquartered in San Diego, California. The company serves customers and patients in markets around the world through a global network of operations, distributors and healthcare partners. Mick Farrell has served as ResMed’s chief executive officer since 2013.

Key Stats

• Today's Range: $226.42 to $231.36
• 50-Day Range: $211.39 to $240.47
• 52-Week Range: $180.26 to $277.85
• Volume: 440,835 shs
• Average Volume: 1.30 million shs
• Market Capitalization: $32.42 billion
• P/E Ratio: 22.09
• Dividend Yield: 1.15%
• Price Target: $241.69
• Consensus Rating: Hold

ResMed Stock Analysis - MarketRank™

ResMed scored higher than 72% of companies evaluated by MarketBeat, and ranked 160th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

ResMed has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 7 buy ratings, 9 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for ResMed is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

ResMed has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.62%

Earnings Growth

Earnings for ResMed are expected to grow by 8.62% in the coming year, from $12.07 to $13.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ResMed is 22.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of ResMed is 22.01, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.63.

Price to Earnings Growth Ratio

ResMed has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ResMed has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.91% of the float of ResMed has been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 11.74, which indicates bearish sentiment.

Change versus previous month

Short interest in ResMed has recently increased by 8.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

ResMed pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

ResMed has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of ResMed is 25.31%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, ResMed will have a dividend payout ratio of 20.14% next year. This indicates that ResMed will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.64

News Sentiment

ResMed has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for ResMed this week, compared to 6 articles on an average week.

Search Interest

11 people have searched for RMD on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,294,098.00 in company stock.

Percentage Held by Insiders

0.58% of the stock of ResMed is held by insiders.

Percentage Held by Institutions

54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Record date for 9/24 Dividend: 8/20/2026
• Ex-Dividend for 9/24 Dividend: 8/20/2026
• Dividend Payable: 9/24/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 10/29/2026
• AGM 2026: 11/18/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:RMD
• CIK: 943819
• Web: www.resmed.com
• Phone: (858) 836-5000
• Fax: 858-836-5501
• Employees: 11,370
• Year Founded: 1994

Price Target and Rating

• Average Price Target for ResMed: $241.69
• High Price Target: $300.00
• Low Price Target: $213.00
• Potential Upside/Downside: +4.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.43
• Trailing P/E Ratio: 22.09
• Forward P/E Ratio: 19.09
• P/E Growth: 1.42
• Net Income: $1.52 billion
• Net Margins: 26.94%
• Pretax Margin: 33.95%
• Return on Equity: 25.58%
• Return on Assets: 18.89%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.10
• Quick Ratio: 2.42

Sales & Book Value

• Annual Sales: $5.65 billion
• Price / Sales: 5.73
• Cash Flow: $13.19 per share
• Price / Cash Flow: 17.47
• Book Value: $45.40 per share
• Price / Book: 5.07

Miscellaneous

• Outstanding Shares: 140,640,000
• Free Float: 139,823,000
• Market Cap: $32.40 billion
• Optionable: Optionable
• Beta: 0.75